Oncology News

This award goes to a patient advocate or advocacy group that moved the needle on a disease in regard to discussion in the public sphere, better communication between patients and providers and/or advocacy for legislative or regulatory action (drug approvals, insurance coverage, etc).

This award goes to a woman in the field who has emerged as a leader and as an example to younger women of how a successful career can unfold.

This award goes to a physician who has made meaningful change to overcome the social determinants of health in gastroenterology. The awardee is seen as a model of how identifying and addressing social determinants of health can better patient care.

The COVID-19 pandemic created new barriers for colorectal cancer screening. However, fecal occult blood tests done at home may boost colonoscopy compliance, according to a presentation at the American College of Surgeons Clinical Congress.

A phase 3 trial designed to assess trifluridine and tipiracil plus bevacizumab as first-line treatment for certain patients with advanced colorectal cancer missed its primary endpoint.

This month’s cover story highlights the growing burden of hepatocellular carcinoma, the most common type of primary liver cancer, in the United States. Despite being a cancer that does not typically receive much attention, HCC is projected to become the third leading cause of cancer-related death in the United States by 2040 if current trends continue. Its increasing mortality is related to a growing number of cases in the setting of non-alcoholic fatty liver disease, the liver manifestation of the metabolic syndrome, and a high proportion of HCC cases being detected at a late stage. While patients detected at an early stage are amenable to curative therapies such as liver transplantation and have a median survival exceeding 5 years, those diagnosed at a late stage traditionally have had limited therapeutic options and a median survival of only 1 year.

Liver cancer — the fastest-growing cause of cancer death in the U.S. — has been notoriously difficult to treat.

Patients with pediatric onset inflammatory bowel disease may have a higher risk for cancer and death, according to a presentation at UEG Week Virtual 2021.

Healio Gastroenterology presents the following report on the top stories from UEG Week 2021.

The addition of tremelimumab to first-line durvalumab significantly improved OS compared with sorafenib for certain patients with unresectable hepatocellular carcinoma, according to topline data released by the agent’s manufacturer.